Arena Pharmaceuticals (NASDAQ:ARNA), one of a trio of companies developing treatments for the obesity market, released its Q3 earnings after the market closed yesterday. Despite a fairly neutral report -- which didn't include sales projections for its FDA-approved drug Belviq -- the company is trading down today.
In the following video, health care analysts Max Macaluso and Brenton Flynn examine Arena's results, including a new partnership deal, and discuss the cascading effects of the poor sales figures reported by Arena's main competitor, VIVUS (NASDAQ:VVUS).
Max Macaluso, Ph.D. and Brenton Flynn have no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.